(Q39895097)

English

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability (English)

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

object named as

Tawanda Gumbo

1

0 references

language of work or name

0 references

publication date

19 January 2010

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

54

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

4

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

1484-1491

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Interpretation of antibiotic concentration ratios measured in epithelial lining fluid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Setting and revising antibacterial susceptibility breakpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Ethambutol dosage for the treatment of children: literature review and recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Prevalence of overweight and obesity in the United States, 1999-2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Intrapulmonary concentrations of pyrazinamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

22 September 2017

Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

17 June 2018

Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

17 June 2018

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

17 June 2018

MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

17 June 2018

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

17 June 2018

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Low-dose inhaled versus standard dose oral form of anti-tubercular drugs: concentrations in bronchial epithelial lining fluid, alveolar macrophage and serum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

20 August 2018

Meningeal Tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

2 December 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849358

2 December 2018

Pyrazinamide-isoniazid in low dosage in treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pulmonary impairment after tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculous meningitis in a country with a low incidence of tuberculosis: still a serious disease and a diagnostic challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling of individual pharmacokinetics for computer-aided drug dosage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis--evaluation of interlaboratory precision and interpretive compatibility w

1 reference

https://pubmed.ncbi.nlm.nih.gov/20086150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.01474-09

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39895097&oldid=2143842475"